Downloading...
Download

Wegovy

HIMS puked up its Wegovy today!Hims & Hers Health HIMS shares were down more than 34.63% in Monday trading, while Novo Nordisk NVO stock was down over 5% after Novo Nordisk said it has halted its collaboration with Hims & Hers on the sale of weight loss drugs, including Wegovy. The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform. Novo Nordisk said direct access to the drug would no longer be available through Hims & Hers Health because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." This stock failed to catch a bid despite the equity markets strong.
NYSE:HIMS
by Trading-Capital
3
Novo Nordisk | NVO | Long at $86.74The Good: NYSE:NVO expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration's official shortage list. Just reported better-than-expected net profit in Q4 2024, amid soaring demand for its obesity drugs. Revenues for the Q4 2024 came in at $11.6 billion, up 30% compared to the same quarter in 2023. From a technical analysis perspective, hovering near my historical simple moving average which may lead to a near-term price increase due to positive earnings The Bad: Slower growth in 2025 (16%-24% for 2025 vs 18%-26% in 2024). Chart has been on a major run since 2020 and may be due for further correction. Personally, the positives outweigh the negatives given the obesity drug demand. Thus, at $86.74, NYSE:NVO is in a personal buy zone. Targets: $96.00 $105.00
NYSE:NVOLong
by WorthlessViews
Novo Nordisk's Wegovy Secures China Approval, Poised for Major MDanish pharmaceutical giant Novo Nordisk gains significant access with the approval of its weight-loss drug Wegovy in China. This move grants Novo Nordisk entry into the world's second-largest economy, targeting a growing population facing obesity challenges. Key Considerations: Wegovy targets patients with a Body Mass Index (BMI) of 30 or higher alongside weight-related comorbidities like hypertension and type 2 diabetes. The approval coincides with the impending expiration of the semaglutide patent in 2026, potentially intensifying competition with generic alternatives. Novo Nordisk adopts a strategic initial focus on self-pay patients in China, mirroring its approach in other regions for early adoption before broader insurance coverage. Competition emerges from Eli Lilly's weight-loss product Zepbound and domestic Chinese drug manufacturers. Wegovy's potential for success in China aligns with the remarkable growth of Novo Nordisk's diabetes drug Ozempic (sharing the same active ingredient), which saw sales double in the region last year. Novo Nordisk demonstrates a proactive commitment to meeting the global demand for weight-loss solutions through substantial investments in production capacity. Maintaining leadership in this market requires a continued focus on innovation, strategic expansion, and effective market penetration strategies as the semaglutide patent nears expiration. The approval of Wegovy represents a significant milestone for both Novo Nordisk and China's public health efforts in addressing obesity. While this marks a new chapter in global weight-loss treatment, the competitive landscape promises to intensify. Novo Nordisk's future success hinges on its ability to navigate this evolving market.
NYSE:NVOLong
by MorMedia